-
US vows 'economic asphyxiation' of Iran with new sanctions
-
Saudi Arabia to invest $7 bn in theme parks near Paris: French presidency
-
French tourist dies after getting stuck in scorching Death Valley
-
Vuelta stage three abandoned in dangerous weather conditions
-
US proposes expanding UN Sudan arms embargo to entire country
-
Banned Vondrousova appeals doping suspension to CAS
-
Ceasefire verification mission heads to east DR Congo
-
Ukraine's allies pledge to continue support despite Russian threats
-
Carse dropped from England squad after nightclub incident
-
France readies high school phone ban for next month
-
Empire State Building climbers kiss outside court after viral proposal
-
Trump says to double tariffs on Canada autos as trade fight heats up
-
French poll shows Le Pen's biggest challenger may be hard left's Melenchon
-
Noosha Aubel: Hur mycket administrativt misslyckande tål Potsdam till?
-
Noosha Aubel: Πόση διοικητική αποτυχία μπορεί να αντέξει ακόμα το Πότσδαμ?
-
WeGolden Receives Best Gold Trading Platform Asia 2026 Recognition from TrustFinance Awards
-
WeMasterTrade Receives Best Instant Prop APAC 2026 Recognition from TrustFinance Awards
-
BtcDana Wins “Best Customer Support Experience – CFD Broker 2026” at the TrustFinance Performance Awards
-
MH Markets Recognized as Most Transparent Broker at the TrustFinance Awards 2026
-
Belgian pie-thrower, scourge of celebrities, dies at 80
-
Stocks, oil slip ahead of US threat of economic war against Iran
-
Eto'o urges support for embattled FIFA president Infantino
-
Trump claims Iran 'collapsing' as US threatens 'economic D-Day'
-
India in driver's seat in second Sri Lanka Test
-
Noosha Aubel: Kolik administrativních selhání ještě Potsdam snese?
-
Noosha Aubel: Ile jeszcze nieudolności administracyjnej wytrzyma Poczdam?
-
Нуша Аубель: Скільки ще Потсдам витримає адміністративних провалів?
-
نوشا أوبيل: إلى أي مدى ستتحمل بوتسدام المزيد من الفشل الإداري؟
-
努莎·奧貝爾:波茨坦還能承受多少行政失職?
-
누샤 아우벨: 포츠담은 행정 실패를 얼마나 더 견뎌낼 수 있을까?
-
ヌーシャ・オーベル:ポツダムは、あとどれだけの行政の失態に耐えられるのか?
-
नूशा ऑबेल: पॉट्सडैम और कितनी प्रशासनिक विफलता सहन कर सकता है?
-
Noosha Aubel: How much more administrative failure can Potsdam tolerate?
-
Нуша Аубель: Сколько ещё Потсдам сможет выдержать административных провалов?
-
Despair and anger in Conakry after deadly landfill collapse
-
Liverpool must improve on 'unacceptable' season, says Van Dijk
-
OSCE says Kazakh elections lacked choice after ruling party wins landslide
-
UK PM dismisses Russian threats as Ukraine allies gather in Kyiv
-
India declare on 503-9 after Jurel hundred
-
Attacks on Red Cross in DR Congo making Ebola fight 'harder'
-
Kremlin says UK preventing peace by giving missile info to Ukraine
-
Oil falls ahead of US plan for economic war on Iran
-
Springboks change half-backs for second All Blacks Test
-
Millions of Teslas recalled in China over door handle safety
-
Jurel hits 95 not out as India reach 475-8 at tea in Sri Lanka Test
-
IUX Launches New Education Webinar Series to Support Traders’ Financial Literacy
-
Ingebrigtsen buoyed by fourth in Diamond League comeback
-
Dutch say won't participate in 'no longer' neutral Eurovision
-
Kenyans get creative to join manga cosplay craze
-
Kenyan farmers turn to bugs as organic demand grows
Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 16, 2025 / Bionoid Pharma Inc. (OTC PINK:BINP) proudly announces its corporate rebranding to AI Maverick Intel, Inc., marking a significant transformation in its strategic direction. This change underscores the company's commitment to leveraging advanced artificial intelligence technologies to revolutionize customer acquisition and engagement across healthcare, biotech, and other sectors.
The rebranding follows the successful acquisition of AI Maverick Intel, a leading platform renowned for its proprietary AI solutions that automate and enhance audience engagement. The platform's capabilities enable intelligent, two-way communication and data-driven interactions, positioning the company at the forefront of AI-driven business solutions.
"Our evolution into AI Maverick Intel, Inc. signifies more than a name change; it represents our dedication to pioneering AI technologies that drive meaningful engagement and sustainable growth," said Wayne Cockburn, CEO of AI Maverick Intel, Inc. "By integrating cutting-edge AI solutions, we are poised to deliver unparalleled value to our clients and stakeholders."
The company's flagship AI Maverick platform is designed to streamline customer acquisition processes, enabling businesses to identify, reach, and engage their target audiences with unprecedented efficiency and precision. This strategic shift aligns with the company's vision to become a leader in AI-driven solutions that foster innovation and long-term value creation.
For more information about AI Maverick Intel, Inc. and its innovative AI solutions, please visit https://aimaverickintel.com/
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. Bionoid aims to deliver long-term value through innovation, efficiency, and strategic partnerships.
Stay Connected:
Website | AI Maverick | OTC:BINP | X: @BionoidPharminc
Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma Inc.
View the original press release on ACCESS Newswire
D.Johnson--AT